decemb
januari
four
sar
case
identifi
guangzhou
guangdong
provinc
china
patient
male
televis
produc
fever
headach
develop
decemb
patient
femal
waitress
becam
ill
decemb
patient
male
businessman
fever
develop
decemb
patient
male
hospit
director
practic
physician
becam
ill
januari
patient
temperatur
xray
evid
pneumonia
confirm
case
sar
defin
clinic
compat
ill
laboratoryconfirm
evid
sarscov
infect
initi
test
center
diseas
control
prevent
guangdong
provinc
center
diseas
control
prevent
guangzhou
laboratori
laboratori
particip
studi
list
tabl
posit
sarscov
prompt
systemat
collect
clinic
specimen
includ
respiratori
secret
urin
stool
serum
collect
differ
time
point
patient
ill
confirmatori
test
perform
institut
viral
diseas
control
prevent
institut
communic
infect
diseas
china
center
diseas
control
laboratori
b
member
sar
refer
verif
laboratori
network
includ
govern
viru
unit
depart
microbiolog
queen
mari
hospit
hong
kong
special
administr
region
laboratori
c
us
center
diseas
control
prevent
laboratori
serum
specimen
test
laboratori
b
c
neutral
antibodi
sarscov
microneutr
assay
use
procedur
sui
et
al
differ
viru
strain
laboratori
urbani
strain
laboratori
b
laboratori
c
strain
briefli
serial
dilut
prepar
ad
triplic
plate
costar
corn
ny
approxim
pfu
sarscov
ad
dilut
serum
sampl
incub
min
vero
cell
x
ad
well
mixtur
incub
day
result
visual
stain
well
crystal
stain
reagent
crystal
violet
ethanol
formaldehyd
moll
phosphatebuff
salin
pb
h
room
temperatur
neutral
titer
measur
reciproc
highest
serum
dilut
complet
inhibit
vero
cell
lysi
least
two
three
triplic
well
laboratori
b
c
perform
serolog
test
antibodi
use
indirect
enzym
immunoassay
eia
kit
beij
bgigbi
biotech
co
beij
china
accord
manufactur
instruct
briefli
dilut
serum
specimen
ad
sarscov
well
incub
min
well
rins
wash
solut
incub
conjug
antibodi
solut
min
wash
substrat
solut
ad
well
incub
min
dark
termin
solut
ad
optic
densiti
od
measur
use
nm
refer
wavelength
nm
everi
assay
one
blank
control
one
posit
control
two
neg
control
well
includ
cutoff
valu
posit
test
defin
plu
mean
od
neg
control
well
specimen
consid
posit
sarscov
antibodi
calcul
valu
observ
od
read
minu
od
read
blank
control
exceed
cutoff
valu
laboratori
perform
serolog
test
sar
inhous
indirect
eia
briefli
serial
dilut
serum
specimen
ad
microtit
plate
dynatech
laboratori
inc
chantilli
va
precoat
either
sarscov
lysat
urbani
strain
vero
cell
lysat
incub
h
rins
plate
incub
goat
antihuman
immunoglobulin
ig
g
iga
igm
conjug
horseradish
peroxidas
kirkegaard
perri
laboratori
inc
gaithersburg
md
h
wash
sulfon
acid
abt
substrat
kirkegaard
perri
laboratori
inc
ad
min
od
measur
nm
nm
wavelength
specimen
consid
posit
sarscov
antibodi
adjust
sum
od
sum
differ
sarscov
antigen
control
antigen
well
dilut
exceed
titer
specimen
titer
specimen
taken
highest
dilut
posit
adjust
od
valu
laboratori
perform
inhous
immunofluoresc
assay
ifa
briefli
sarscov
strain
vero
cell
spot
acetonefix
glass
slide
prepar
advanc
test
serum
sampl
start
dilut
deposit
onto
slide
incub
min
slide
rins
blotdri
fluoresceinlabel
polyval
antihuman
immunoglobulin
biosourc
intern
camarillo
ca
ad
incub
min
slide
rins
twice
mount
phosphatebuff
glycerol
coverslip
examin
uv
microscop
immunofluoresc
titer
taken
highest
dilut
show
posit
reaction
appl
green
fluoresc
cytoplasm
granul
laboratori
c
perform
similar
ifa
modifi
use
sarscov
strain
cell
microneutr
assay
human
coronavirus
develop
studi
laboratori
rhabdomyosarcoma
rd
cell
grown
confluenc
dulbecco
modifi
eagl
medium
dmem
gibcoinvitrogen
carlsbad
ca
contain
defin
fetal
bovin
serum
fb
hyclon
logan
ut
atcc
atcc
introduc
onto
wash
monolay
cultur
incub
day
infect
cultur
submit
three
freezeandthaw
cycl
clarifi
lowspe
centrifug
store
viru
stock
titrat
ad
dilut
eight
replic
per
dilut
cultur
plate
costar
cambridg
follow
ad
x
rd
cellsml
incub
day
infect
well
identifi
immunofluoresc
assay
describ
elsewher
use
monoclon
antibodi
specif
nucleo
protein
tissuecultur
infect
dose
determin
method
reed
muench
microneutr
assay
heatinactiv
human
anim
control
hyperimmun
serum
sampl
serial
twofold
dilut
fbsdmem
triplic
well
sampl
dilut
duplic
tissu
cultur
plate
follow
ad
h
incub
x
rd
cellsml
ad
plate
incub
day
back
titrat
includ
test
neutral
titer
defin
reciproc
highest
serum
dilut
complet
inhibit
fluoresc
least
two
three
triplic
well
laboratori
c
perform
inhous
ifa
describ
sarscov
modifi
use
cell
laboratori
perform
serolog
test
human
coronavirus
use
inhous
indirect
eia
briefli
microtit
plate
dynatech
laboratori
coat
overnight
previous
optim
concentr
clarifi
lysat
uninfect
rd
cell
prepar
microneutr
assay
serial
dilut
serum
specimen
ad
incub
h
wash
plate
incub
h
goat
antihuman
igg
conjug
horseradish
peroxidas
sigma
st
loui
mo
similar
wash
tetramethyl
benzidin
substrat
zyme
laboratori
san
francisco
ca
ad
incub
min
room
temperatur
colorometr
reaction
stop
moll
phosphor
acid
od
measur
dual
wavelength
mode
nm
nm
adjust
sum
od
duplic
well
posit
neg
antigen
determin
serum
dilut
highest
dilut
show
od
taken
virusspecif
igg
antibodi
titer
titer
rise
fourfold
earli
late
serum
pair
consid
evid
recent
infect
respiratori
specimen
stool
test
sarscov
rna
use
realtim
revers
chain
reaction
rtpcr
assay
sever
differ
sourc
laboratori
b
c
use
assay
develop
piji
bioengin
shenzhen
china
artu
gmbh
hamburg
germani
follow
manufactur
instruct
laboratori
use
inhous
realtim
rtpcr
procedur
appropri
rtpcr
control
includ
posit
sar
rna
neg
extract
water
blank
amplif
control
includ
run
addit
laboratori
test
specimen
human
rnase
p
ensur
adequaci
rna
extract
monitor
rtpcr
inhibitor
rtpcr
human
human
perform
throat
swab
degener
consensu
pcr
primer
genu
coronaviru
use
superscript
one
step
rtpcr
kit
invitrogen
primer
deriv
highli
conserv
region
open
read
frame
orf
pol
gene
viral
total
nucleic
acid
process
throat
swab
rtpcr
carri
use
method
previous
describ
sequenc
third
sarscov
genom
obtain
overlap
rtpcr
product
cover
envelop
e
membran
nucleocapsid
n
structur
protein
gene
plu
sever
gap
unknown
function
se
gap
orf
e
orf
mn
gap
orf
e
orf
use
previous
describ
method
viru
isol
attempt
respiratori
specimen
collect
patient
method
previous
describ
briefli
antimicrobi
specimen
introduc
tube
cultur
vero
cell
incub
room
temperatur
h
fresh
modifi
dmem
fetal
calf
serum
ad
cultur
incub
rock
cultur
observ
daili
cytopath
effect
week
blind
passag
neg
cultur
sarscov
confirm
rtpcr
describ
one
serum
specimen
patient
test
posit
sarscov
antibodi
laboratori
use
multipl
assay
format
includ
eia
ifa
neutral
assay
tabl
four
patient
detect
sarscov
antibodi
one
laboratori
earli
ill
serum
specimen
collect
day
onset
patient
posit
laboratori
one
method
specimen
collect
day
patient
posit
eia
perform
laboratori
b
respect
comparison
could
made
pattern
antibodi
respons
similar
assay
fourfold
greater
rise
eia
ifa
antibodi
demonstr
multipl
laboratori
three
four
patient
fourfold
rise
sarscov
antibodi
patient
identifi
one
laboratori
laboratori
ifa
laboratori
laboratori
test
earliest
specimen
patient
test
serum
specimen
arriv
concurr
concurr
rise
antibodi
detect
ifa
laboratori
c
patient
assess
possibl
sar
antibodi
react
sarscov
confound
diagnosi
sar
earli
late
serum
specimen
patient
simultan
test
laboratori
sarscov
antibodi
neutral
assay
eia
tabl
test
rise
either
eia
neutral
antibodi
titer
note
serum
pair
patient
rise
sar
neutral
antibodi
serum
pair
patient
rise
sar
eia
antibodi
tabl
tabl
earliest
acutephas
serum
specimen
patient
unavail
test
neutral
antibodi
titer
detect
detect
lower
titer
sarscov
previou
studi
shown
lack
sarscov
antibodi
pair
serum
specimen
patient
acut
infect
varieti
specimen
test
sarscov
cultur
isol
sarscov
rna
multipl
realtim
rtpcr
assay
tabl
although
viru
success
isol
respiratori
specimen
viral
rna
detect
rtpcr
sever
respiratori
specimen
patient
two
laboratori
one
laboratori
singl
stool
specimen
patient
contrast
respiratori
specimen
neg
coronavirus
rtpcr
throat
swab
collect
day
patient
day
patient
amount
viral
rna
specimen
small
shown
threshold
cycl
valu
realtim
rtpcr
assay
inconsist
posit
laboratori
day
throat
swab
patient
none
type
specimen
includ
multipl
stool
stool
swab
specimen
three
patient
test
posit
sarscov
rna
throat
swab
collect
day
patient
suffici
viral
rna
initi
sequenc
studi
sequenc
confirm
sarscov
close
match
isol
civet
cat
taken
novemb
decemb
wild
anim
market
guangdong
provinc
extens
descript
sequenc
present
followup
report
particip
multipl
laboratori
studi
document
sarscov
infect
patient
permit
comparison
result
obtain
differ
assay
antibodi
test
provid
rel
earli
indic
sarscov
infect
four
patient
earli
day
later
day
onset
ill
sarscov
antibodi
reportedli
detect
earli
day
onset
commonli
detect
day
although
earli
appear
antibodi
consist
antibodi
respons
seen
sar
outbreak
could
also
indic
differ
outbreak
exampl
patient
may
longer
incub
period
may
previous
infect
sarslik
coronaviru
prime
immun
system
rapid
anamnest
antibodi
respons
longer
incub
period
possibl
low
viru
inoculum
infect
viru
replic
less
effici
could
provid
addit
time
mount
antibodi
respons
lead
appar
rapid
antibodi
induct
sarscov
isol
patient
viral
rna
detect
patient
rel
low
level
find
consist
result
studi
outbreak
suggest
high
viru
titer
associ
sever
ill
effici
viru
transmiss
patient
surviv
none
show
evid
transmiss
other
one
stool
specimen
one
patient
patient
collect
week
ill
posit
sarscov
rna
find
contrast
report
outbreak
high
percentag
stool
specimen
collect
week
ill
posit
sarscov
rtpcr
stool
specimen
like
posit
specimen
week
ill
low
viru
titer
found
patient
may
reflect
infect
acquir
directli
anim
viru
acquir
genet
chang
facilit
infect
human
sequenc
data
recent
report
chines
sar
molecular
epidemiolog
consortium
suggest
sarscov
may
adapt
human
outbreak
author
note
protein
gene
higher
ratio
code
noncod
chang
earli
stage
outbreak
compar
later
stage
find
suggest
select
advantag
code
chang
presum
relat
infect
human
consist
find
coronavirus
amino
acid
chang
protein
affect
tissu
tropism
diseas
associ
infect
previous
unrecogn
concern
potenti
serolog
crossreact
human
coronavirus
sarscov
cours
workup
patient
one
laboratori
show
antibodi
respons
sarscov
one
patient
reaction
unexpect
requir
test
definit
determin
viru
induc
antibodi
respons
subsequ
neutral
eia
antibodi
result
demonstr
sarscov
coronavirus
induc
antibodi
detect
weight
evid
therefor
suggest
patient
infect
sarscov
coronavirus
find
reinforc
need
better
understand
mechan
underli
appar
crossreact
sarscov
human
coronavirus
nonneutr
serolog
assay
case
illustr
diagnost
difficulti
occur
evalu
patient
sar
abil
confid
confirm
negat
diagnosi
allow
control
effort
focu
import
case
minim
unnecessari
social
econom
disrupt
cost
miss
case
high
spread
occur
cost
falseposit
diagnosi
patient
famili
member
healthcar
facil
commun
also
substanti
respons
establish
sar
refer
verif
laboratori
network
verifi
suspect
case
sarscov
infect
outsid
countri
case
occur
group
also
begun
provid
test
sampl
profici
panel
allow
laboratori
assess
assay
perform
guidelin
specimen
manag
minim
chanc
contamin
rapid
identif
confirm
sarscov
infect
four
case
exemplifi
success
collabor
local
network
laboratori
highlight
import
continu
cooper
event
appear
new
sar
case
